Yang, Teng-KaiTeng-KaiYangYu, Ya-FangYa-FangYuCHIAO-LING TSAILi, Hsing-JuHsing-JuLiYang, Po-ShengPo-ShengYangKAI-WEN HUANGCHIA-HSIEN CHENG2022-11-072022-11-072022-10-211471-2407https://scholars.lib.ntu.edu.tw/handle/123456789/624484Cancer therapy has evolved from non-specific cytotoxic agents to a selective, mechanism-based approach that includes targeted agents and immunotherapy. Although the response to targeted therapies for unresectable hepatocellular carcinoma (HCC) is acceptable with the improved survival, the high tumor recurrence rate and drug-related side effects continue to be problematic. Given that immune checkpoint inhibitor alone are not robust enough to improve survival in unresectable HCC, growing evidence supports the combination of targeted therapy and immunotherapy with synergistic effect.enImmunotherapy; Meta-analysis; Systematic review; Targeted therapy; Unresectable hepatocellular carcinoma[SDGs]SDG3journal article10.1186/s12885-022-10174-6362713742-s2.0-85140340565WOS:000871074900001https://api.elsevier.com/content/abstract/scopus_id/85140340565